Experiences and treatment patterns of hypogonadal men in a U.S. health system

International Journal of Clinical Practice

Volumn 68, Issue 10, 2014, Pages 1257-1263

  Shortridge, E F ^a   Polzer, P ^a   Donga, P ^b   Blanchette, C M ^b   Fang, Y ^b   Burudpakdee, C ^b   Carswell, B ^c  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

^c Reliant Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HEALTH CARE COST; HEALTH SURVEY; HELP SEEKING BEHAVIOR; HUMAN; HYPOGONADISM; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SYMPTOM; UNITED STATES; ADOLESCENT; EUNUCHISM; HORMONE SUBSTITUTION; MIDDLE AGED; PSYCHOLOGY;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TESTOSTERONE; UNITED STATES;

EID: 84908228286     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12418     Document Type: Article

References (31)

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
2. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514.
3. Araujo AB, Esche GR, Kupelain V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247.
4. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-769.
5. Moskovic DJ, Araujo AB, Lipshultz LI, et al. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med 2013; 10: 562-569.
6. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010; 7: 1627-1656.
7. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest 2012; 35: 104-120.
8. Wilson IB, Cleary PD,. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273: 59-65.
9. Lackner JE, Rücklinger E, Schatzl G, et al. Are there symptom-specific testosterone thresholds in aging men? BJU Int 2011; 108: 1310-1315.
10. Dugan E, Roberts CP, Cohen SJ, et al. Why older community-dwelling adults do not discuss urinary incontinence with their primary care physicians. J Am Geriatr Soc 2001; 49: 462-465.
11. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-2098.
12. Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011; 75: 836-843.
13. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91: 69-74.
14. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 2001; 54: 739-750.
15. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-5926.
16. McKinlay JB, Link C,. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol 2007; 52: 389-396.
17. Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810-1818.
18. Heinemann LAJ, Zimmermann T, Vermeulen A, et al. A new 'Aging Males' Symptoms' (AMS) rating scale. Aging Male 1999; 2: 105-114.
19. Daig I, Heinemann LA, Kim S, et al. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003; 1: 77.
20. Moore C, Huebler D, Zimmermann T, et al. The Aging Males' Symptoms Scale (AMS) as Outcome Measure for Treatment of Androgen Deficiency. Eur Urol 2004; 46: 80-87.
21. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 2009; 18: 873-880.
22. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-598.
23. Harman SM, Metter EJ, Tobin JD,. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731.
24. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-2745.
25. O'Connor DB, Corona G, Forti G, et al. Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study sexual function questionnaire. J Sex Med 2008; 5: 1374-1385.
26. Holden CA, McLachlan RI, Pitts M, et al. Determinants of male reproductive health disorders: the men in Australia telephone survey (MATeS). BMC Public Health 2010; 10: 96.
27. Kaltenboeck A, Foster S, Ivanova J, et al. The direct and indirect costs among U.S. privately insured employees with hypogonadism. J Sex Med 2012; 9: 2438-2447.
28. Schoenfeld MJ, Shortridge E, Cui ZL, et al. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med 2013; 10: 1401-1409.
29. National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics (US), 2011.
30. Surampudi PN, Wang C, Swerdloff R,. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012; 2012: 625434.
31. Rhoden EL, Morgentaler A,. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010; 7: 277-283.